HUYABIO International today announced statistically significant and clinically meaningful topline results from its global Phase 3 clinical trial evaluating HBI-8000 in combination with nivolumab for patients with advanced melanoma, bringing the company one step closer to a potential new frontline treatment option for one of the deadliest forms of skin cancer.
This is the newest page. Registered accounts read further back.